Intech Investment Management LLC Invests $526,000 in InMode Ltd. (NASDAQ:INMD)

Intech Investment Management LLC purchased a new position in InMode Ltd. (NASDAQ:INMD) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 31,040 shares of the healthcare company’s stock, valued at approximately $526,000.

Other hedge funds also recently bought and sold shares of the company. Doma Perpetual Capital Management LLC lifted its position in InMode by 210.7% in the 2nd quarter. Doma Perpetual Capital Management LLC now owns 2,011,240 shares of the healthcare company’s stock valued at $36,685,000 after acquiring an additional 1,363,841 shares in the last quarter. Federated Hermes Inc. lifted its holdings in shares of InMode by 191.9% during the second quarter. Federated Hermes Inc. now owns 1,125,017 shares of the healthcare company’s stock valued at $20,520,000 after purchasing an additional 739,629 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of InMode by 63.6% during the second quarter. Acadian Asset Management LLC now owns 1,124,887 shares of the healthcare company’s stock valued at $20,502,000 after buying an additional 437,122 shares during the last quarter. Lombard Odier Asset Management Europe Ltd bought a new stake in InMode in the 2nd quarter worth about $4,104,000. Finally, Systematic Financial Management LP raised its position in InMode by 34.5% in the 2nd quarter. Systematic Financial Management LP now owns 866,619 shares of the healthcare company’s stock worth $15,807,000 after buying an additional 222,532 shares during the last quarter. Institutional investors own 68.04% of the company’s stock.

InMode Trading Up 0.2 %

INMD opened at $19.53 on Monday. The company’s 50 day moving average is $17.60 and its 200 day moving average is $17.49. The company has a market cap of $1.64 billion, a price-to-earnings ratio of 10.56 and a beta of 2.15. InMode Ltd. has a 12-month low of $14.87 and a 12-month high of $26.80.

Wall Street Analysts Forecast Growth

INMD has been the topic of a number of recent analyst reports. BTIG Research initiated coverage on shares of InMode in a report on Thursday, October 17th. They set a “buy” rating and a $25.00 price target on the stock. Barclays cut their target price on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, October 14th. Finally, Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, InMode currently has an average rating of “Hold” and a consensus target price of $22.60.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.